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A breakdown in intestinal homeostasis results in inflammatory bowel diseases. including coeliac
disease and allergy. Galectins, evolutionarily conserved p-galactoside-binding proteins, can modulate
immune-epithelial cell interactions by influencing immune cell fate and cytokine secretion. In this study
we investigated the 'glycosylation signature' as well as the regulated expression of galectin-l and -3 in
human duodenal samples of allergic and non-allergic children. Whereas galectin-l was predominantly
localized in the epithelial compartment (epithelial cells and intraepithelial lymphocytes) and the
underlying lamina propria (T cells, macrophages and plasma cells), galectin-3 was mainly expressed by
crypt epithelial cells and macrophages in the lamina propria. Remarkably, expression of these galectins
was not significantly altered in allergic versus non-allergic patients. Investigation of the glycophenotype
of the duodenal inflammatory microenvironment revealed substantial a2-6-linked sialic acid bound to
galactose in lamina propria plasma cells, macrophages and intraepithelial lymphocytes and significant
levels of asialo core 1 O-glycans in CD68+macrophages and enterocytes. Galectin-l preferentially bound
to neutrophils, plasma cells and enterocytes, while galectin-3 binding sites were mainly distributed on
macrophages and intraepithelial lymphocytes. Notably, galectin-3, but not galectin-l binding, was
substantially increased in intraepithelial gut lymphocytes of allergic patients compared to non-allergic
subjects, suggesting a potential role of galectin-3-glycan interactions in shaping epithelial-immune cell
connections during allergic inflammatory processes.
Food allergies are becoming increasingly common
worldwide. They consist of a spectrum of disorders
that result from adverse immune responses to dietary
antigens (1). Hypersensitivity to cow milk allergy is
one of the most common food allergies in childhood
and constitutes a pathological condition in which
oral tolerance against luminal cow's milk proteins
is abrogated (1). Although the precise pathogenic
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mechanisms are unknown, immunological responses
to food may be IgE- or non-IgE- mediated. It seems
possible that during the chronic phase ofan originally
IgE-initiated allergic inflammation, the pathogenic
immune reaction responsible for clinical symptoms
is dominated by allergen-specific T lymphocytes.
In this context, it has become increasingly evident
that allergen-specific Th2 cells play a central role
in the genesis and maintenance of the allergic
inflammatory reactions in both human subjects and
mouse models (2-3). On the other hand, cell mediated
immunity has been implicated in IgE-independent
gastrointestinal food hypersensitivity. Activation of
cytotoxic T lymphocytes has been described as the
main pathogenic mechanism in cow's milk protein
sensitive enteropathy (CMSE) (4).
Glycan structures, which decorate the surfaces of
all mammalian cells, can substantially change under
different physiological and pathological conditions
(5). In fact, glycosylation of cell surface proteins
can control critical immunological processes,
including T-cell activation, migration and apoptosis
(6-7). Therefore, the physiology and pathology of a
cell is determined to a great extent by the complex
information encoded by its cell surface glycosylation
pattern, which is decoded by various glycan-binding
proteins, including C-type lectins, siglecs and
galectins (5, 8-9).
Galectins, a family of highly conserved
carbohydrate-binding proteins, are characterized
by their ability to recognize multiple N-
acetyllactosamine residues, which can be
displayed on both N- and O-glycans on cell surface
glycoconjugates (8). Galectins have emerged as
novel regulators ofimmune cell homeostasis. Results
from our laboratory demonstrated that galectin-I
(Gal)-l contributes to r immune cell tolerance by
selectively eliminating Thl and Th17 pathogenic
cells, thus promoting a shift toward a Th2-dominant
cytokine profile (6, 10) or by favoring the expansion
of regulatory T cells (11-12). On the other hand,
Gal-3 induces activation of various inflammatory
cell types (13), modulates T-cell apoptosis (13-14)
and induces a pro-inflammatory response (13, 15).
However, Gal-3 can also have anti-inflammatory
activity under certain circumstances (16).
Although the role of galectins in inflammatory
and allergic processes has been extensively described
(13, 15-16), the relevance of these glycan-binding
proteins within the intestinal microenvironment
is poorly understood. Considering that the
duodenum is an intestinal region critical during the
development of allergic responses to food antigens,
and that Th2 cells and IELs are deeply involved in
their pathogenesis, we investigated the binding of
Gal-I, Gal-3 and plant lectins to human duodenum
samples of allergic and non-allergic patients, as
well as the regulated expression of these glycan-
binding proteins, in an attempt to characterize the
human intestinal 'glycosylation signature' under
physiological and pathological conditions, and to
further delineate the potential role ofgalectin-glycan
lattices within the intestinal microenvironment.
MATERIALS AND METHODS
Human samples and patients
The study group consisted of 16patients (8 females and
8 males; mean age 1.5; range 1month to 5 years) diagnosed
as cow milk allergic (n: 8; mean age, 1.8 years; range, 1.5
to 2.5 years) or non-allergic (n: 8; sex- and age-matched).
All patients were assisted at the Gastroenterology Unit in
the Sor Maria Ludovica Children's Hospital (La Plata,
Argentina). Upper intestinal endoscopy was performed
under general anesthesia. Biopsy samples were taken
for routine histology, immunohistochemistry, lectin-
histochemistry and confocal microscopic analysis.
Cow milk allergy (CMA) diagnosis was performed on
the basis of clinical suspicion of milk-related symptoms
(prolonged diarrhea, atopic dermatitis or broncoespasm
after the ingestion of cow's milk), elevated total serum
IgE levels and the presence of cow milk specific IgE
antibodies. Parasitic infections and lactose intolerance
were discarded. Serum IgA levels were normal in all
patients (0.15-1.59 gil). IgG and IgA anti-gliadin and anti-
transglutaminase were found to be negative, and two of
the allergic patients had anemia and blood in stools. After
CMA diagnosis was performed, a strict milk-free diet was
indicated. All patients had clinical remission and showed
a significant increase in weight and height after 6 months
of allergen avoidance. An extensively hydrolyzed cow's
milk formula or a probiotic were indicated as a dairy
substitute during the elimination diet. Written parental
consent was obtained for all patients and the project was
approved by the local Ethics Committee.
Histopathology and immunohistochemical methods
Specimens were fixed in 5% neutral buffered formalin
and embedded in paraffin. Samples were cut and mounted
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onto charged glass slides and heated at 60°C for 30 min.
Briefly, xylene and ethanol were used to deparaffinize and
endogenous peroxidase activity was blocked with 3%
Hpimethanol. Antigen retrieval was performed in buffer
citrate (pH 6) and slides were microwaved. Afterwards,
non-specific sites were blocked with 1% BSA in PBS
and incubated with the primary antibody: anti-CD3
monoclonal antibody (1:25, DAKO, CLONE F7.2.38;
Glostrup, Denmark), biotinylated anti-human IgE (human
c chain specific) (1:500, Vector Labs, Burlingame, CA,
USA), anti-CD45RO monoclonal antibody (1:300,
DAKO, Glostrup, Denmark), anti-ST6Gall polyclonal
antibody (1:200) (Sigma), anti-Gal-l rabbit antibody (1:
200) generated as described (17) and polyclona1anti-Gal-
3 (1:300). The anti-Gal-3 antibody was raised in rabbits
using the purified recombinant Gal-3 (see below), affinity-
purified on Protein A-Sepharose, and its specificity was
validated by Western blot. This was followed by the
appropriate secondary antibodies: anti-mouse IgG-biotin,
anti-rabbit IgG-biotin and strepavidin-HRP conjugate
(DAKO, Glostrup, Denmark). 3,3' -diaminobenzidine
tetrahydrochloride chromogen (DAKO, Glostrup,
Denmark) was used for up to 2 min at room temperature
for immunostaining. A serum from a non-immunized
rabbit was used as primary antibody for specificity
controls. Controls omitting the primary antibody were also
performed. Sections were subsequently counterstained
with 10% hematoxylin and mounted with Eukit. Stained
sections were evaluated by two independent pathologists
blinded to the clinical or endoscopic data.
For routine histology examination the length
of duodenal crypt and villi was assessed using an
ocular micrometer. Giemsa staining was performed to
quantify mast cells, while eosinophils were counted on
hematoxylin-eosin stained sections. Different types of
infiltrating cells were counted per 6 villi.
For lectin-histochemistry, biotinylated lectins were
used as the primary binding reagents: Sambucus nigra
agglutinin (SNA) (25 ug/ml, Vector Labs, Burlingame,
CA, USA), peanut agglutinin (PNA) (25 ug/ml, Vector
Labs, Edelberry; Burlingame, CA, USA), recombinant
Gal-1 (10 ug/ml) generated as described (17) and
recombinant Gal-3 (10 ug/ml). The recombinant Gal-3
was expressed in E. coli from a construct based in the pET
30 Ek/Lic vector (Novagen, Madison, WI), and purified on
a lactosyl-Sepharose column. Streptavidin-HRP (DAKO,
Glostrup, Denmark) was used as secondary reagent.
Controls were performed by omitting the biotinylated
lectins. A Nikon Eclipse E400 microscopy was used to
analyze the slides.
Tissue staining and analysis by confocal microscopy
Immunofluorescence and confocal microscopy were
performed with deparaffinized sections. After antigen
retrieval, samples were incubated with the primary
antibody: anti-CD3 (1:25; DAKO, CLONE F7.2.38,
Glostrup, Denmark), anti-CD68 as a macrophage marker
(1:50; DAKO Clone M7228, Glostrup, Denmark), anti-
CD138 as a plasma cell marker (1:25; DAKO, Clone MI
15, Glostrup, Denmark), or biotinylated lectins (PNA,
SNA, Gal-I and Gal-3) (Vector Labs, Burlingame, CA,
USA). Anti-mouse-Cy3 (1:300; Jackson Immunoresearch
Laboratorioies Inc., PA, USA) or streptavidin-FITC (1:
200; Sigma-Aldrich, St Louis, MO, USA) were used as
secondary reagents. DAPI (Invitrogen, Oregon, USA)
was used for nucleus staining. An LSM 510 Carl Zeiss
Laser Scanning microscope and an LSM5v3.2 software
were used. For negative control staining the primary
antibodies or the biotinylated lectins were replaced by
phosphate-buffered saline.
Validation oflectin binding
Different sugars were used as competitive inhibitors
to validate lectin binding to the glycosylated receptors.
SNA, PNA and galeetin binding were inhibited with 100
mM lactose, 200 mM galactose, and 100 mM lactose
respectively.
Statistical analysis
The data collected were analyzed using the Student's
t test for unpaired data to estimate the significance of the
differences between groups.
RESULTS
Expression and cellular distribution of Gal-l
and Gal-3 in the gut of allergic and non-allergic
patients
To determine the expression of Gal-l and Gal-
3 in duodenal samples of allergic and non-allergic
patients, we first performed a routine histological
examination. Histopathological analysis revealed
no significant differences between samples of non-
allergic and allergic patients (Fig. I). No specific
cellular infiltrates were observed in the gut of
allergic patients, and CD3+ cell, mast cell, eosinophil
and IgE-positive cell counts were not statistically
different when both groups were compared. In
addition, there was no villous atrophy, and villous or
crypt heights were normal in all samples (villi/crypt
ratio of 2.1 ± 0.6).
Several sources of endogenous Gal-I and Gal-3
were found (Fig. 2). Galectin-I was predominantly
expressed in the epithelial compartment, mainly
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Fig. 1.Histopathologic analysis ofduodenal
samples of allergic and non-allergic
patients. Mast cells, eosinophils, IgP
cells, CD45RO+ cells, CD3+ intraepithelial
(IELs) and CD3+ lamina propria (LPLs)
cells were counted in 6 villi of duodenal
samples ofallergic (N: 8) and non-allergic
patients (N: 8). Cells were detected by
Giemsa or hematoxylin/eosin staining.
(mast cells and eosinophils, respectively)
or by immunohistochemistry using anti-IgE,
anti-CD45RO or anti-CD3 monoclonal
antibodies. Statistical analysis revealed
no significant differences between different
groups ofpatients. (Original magnification:
IOOOx except for CD45RO).
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Fig. 2. Expression of Gal-l and Gal-3 in duodenal specimens ofallergic and non-allergic patients. Gal-l and Gal-
3 expression was assessed by immuno-histochemistry using specific polyclonal antibodies against Gal-l and Gal-3
(purified rabbit IgGs) in duodenal samples ofallergic and non-allergic patients. Representative photographs ofmucosa
from allergic and non allergic patients were selected to show Gal-l (A) and Gal-3 (B) positive cells. Control with serum
from non-immunized rabbits is depicted. All samples were analyzed at least three times in independent experiments
(Original magnification: IOOx and 400x).
epithelial cells and intraepithelial lymphocytes
(IELs) and in the underlying lamina propria (T
cells, macrophages and plasma cells), whereas
Gal-3 was mainly found in crypt epithelial cells
and macrophages in the lamina propria (Fig. 2).
Remarkably, expression of these galectins was not
significantly altered in the gut of allergic patients
(Fig. 2), suggesting that the contribution of galectin-
glycan interactions in the transition to allergy may
not be regulated at the level of galectin expression in
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Fig. 3. SNA binding pattern on duodenal samples: Pattern ofa2,6 sialylation in mucosal tissue of allergic versus non-
allergic patients. A) Lectin-h istochemistry using biotinylated-SNA and hematoxylin staining was done to identify SAa2-
6-galactose residues. A photograph with stained IELfrom an allergic patient is shown. B) Co-localization studies using a
Cy3- conjugated anti-CD3 antibody (red), biotinylated SNA/ FITC-conjugated streptavidin (green) and DAPI (blue) was
performed by confocal microscopy. C) Lectin binding inhibit ion assessed by conf ocal microscopy. Cells were incubated
with biotinylated SNA or biotinylated SNA in the presence of 100 mM lactose. D) SNA+cells were quantified by lectin-
histochemistry in biopsy specimens of allergic (N=8) and non-allergic (N=8) patients and no significant difference was
f ound (p= 0.11). E) ST6GaIJ expression was detected using a polyclonal specific antibody by immunoh istochemistry. A
control of immunoreactivity is shown using sera from non-immunized rabbits. All samples were analyz ed at least three
times in independent experiments and representative images are shown (Original magn ifications: 200x and 1000x) .
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Fig. 4. PNA binding pattern in duodenal samples: Detection ofasialo core- I- Osglycans in intestinal glycoproteins of
allergic and non-allergic patients. A) Lectin-histochemistry with biotinylated PNA in gilt biopsies. B) Co-localization
studies by conf ocal microscopy using Cy3-conjugated anti-CD3 antibody (red), biotinylated PNA/ FITC- conjugated
streptavidin (green) and DAPI (blue nuclear staining); (C) Co-localization studies by confocal microscopy using
biotinylated PNA/ FITC-conjugated streptavidin (green) and PE-conjugated anti-CD68 antibody (red). D) Lectin
binding inhibition studies assessed by confocal microscopy using biotinylated PNA/ FITC-Iabeled streptavidin or
biotinylated PNA/ FITC-Iabeled strepta vidin in the presence of 200 mM gala ctose. E) PNA+cells were quantified by
lectin-histochemistry in biopsy spec imens ofallergic and non-allergic patients; no significant differences were found (P:
0.14). All samp les were analyzed at least three times in independent experiments and representative images are shown
(Original magnification: 200x).
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Fig. 5. Gal-l-specifi c ligands on duodenal samples ofallergic and non-allergic patients. A) Lectin-histochemistry with
biotinylated Gal- l/ HRP-conjugated streptavidin ill gut biopsies. B) Co-localization studies by confocal microscopy
using biotinylated Gal-l/ FITC-conjugated streptavidin (green), Cy3 -labeled anti-CD 3 or PE-Iabeled anti-CDI 38 (red)
antibodies and DAPI (blue nuclear staining). C) Lectin binding inhibition studies assessed by confocal microscopy with
biotinylated Gal-l/ FITC-Iabeled streptavidin or biotinylated Gal-l/ FITC-conjugated streptavidin in the presence ofI00
mM lactose. D) Gal-L' cells were quantified by lectin-h istochemistry in biopsy specimens ofallergic and non-allergic
pat ients; no significant differences were found (P= 0.8). All samples were analyzed at least three times in independent
experiments and representative images are shown (Original magnifications: 200x and 400x).
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Fig. 6. Gal-l-specific ligands in duodenal samples of allergic versus non-allergic patients. A) Lectin-histochemistry
with biotinylated Gal-3/ HRP-conju gated streptavidin in gut biopsies from allergic and non-allergic patients. A control
omitting biotinylated Gal-3 is shown. B) Co-localization studies by conf ocal microscopy using biotinylated Gal-3/
FITC-Iabeled streptavidin (green), Cy3-conjugated anti-CD3 (red) and DAPI (blue nuclear staining). C) Lectin binding
inhibition studies by confocal microscopy with biotinylated Gal-3/ FITC-Iabeled streptavidin or biotinylated Gal-3 /
FITC-Iabeled strepta vidin in the presence of I00 mM lactose. D) CD3+IELs and Gal-S: IELs were quantified in samples
ofallergic and non-allergic patients. The ratio ofGal-B: IELs/total CD3+IELs is depicted. All samples were analyzed at
least three times in independent experiments and representative images are shown (Original magnifications: 200x, 400x
and 1000x)
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the intestinal inflammatory microenvironment.
Lectin binding sites within the duodenal
microenvironment in allergic and non-allergic
subjects
To determine whether the transition from 'non-
allergic' to 'allergic' inflammatory human gut is
accompanied by changes in cell surface glycosylation
that could directly affect galectin binding and
immunoregulation, we studied the binding of
exogenous biotin-labeled lectins to mucosal tissues.
It has been demonstrated that incorporation of
a2-6-linked sialic acid to N-glycans may be more
restrictive for the binding of Gal-l but not Gal-3 to
cell surface glycoproteins (6, 18).As depicted in Fig.
3 biotinylated SNA, a plant lectin that recognizes the
sialic acid a2-6-galactose sequence on N-glycans
(6), preferentially bound macrophages of the
lamina propria, although a clear membrane staining
was also observed in intraepithelial lymphocytes.
Double-staining analysis was performed by confocal
microscopy to evaluate the binding of SNA to
CD3+ T lymphocytes. As shown in Fig. 3b, SNA
bound strongly to lamina propria CD3+ T cells.
However, not all CD3+ T cells were positive for
SNA. Remarkably, no significant differences were
found between samples of allergic and non-allergic
patients in the number of CD3+ SNA+ cells (10 ±
1 SNA+CD3+ cell/villi). Importantly, SNA binding
was completely inhibited in the presence of 100
mM lactose, demonstrating that lectin binding was
saccharide-dependent (Fig. 3c). In addition, the
presence of a2-6-linked sialic acid was confirmed
by immunohistochemical analysis of the expression
of a2-6 sialyltransferase 1 (ST6Gal 1), an enzyme
responsible for generating these glycan structures
(Fig 3e). Expression of this glycosyltransferase was
found in plasma cells, T cells and, to a lesser extent,
in epithelial cells of duodenal mucosa. Notably, no
differences were found between allergic and non-
allergic samples.
Next, we probed cell surface glycoreceptors
for the presence of asialo-core-I-O-glycans using
the lectin peanut agglutinin (PNA), which binds
to galactose-B1-3-N-acetylgalactosamine core-l-
O-glycans and thus indicates lack of terminal a2-
3-linked sialic acid on these glycans. Interestingly,
PNA binding correlated well with galectin binding
to the surface of different cell types (6). We found
high PNA binding to intestinal macrophages and
enterocytes (supranuclear granules) (Fig. 4a).
Remarkably, the glycocalyx coat was highly stained
by biotinylated PNA, demonstrating the abundance
of asialo-core l-O-glycans on this structure (Fig 4a).
Using confocal microscopy we found that CD68+
macrophages were highly positive for PNA staining
(Fig. 4b). In contrast, no PNA+CD3+ cells could be
detected, suggesting that CD3+ T cells are highly
sialylated in the intestinal mucosa (Fig. 4c). Specific
binding was demonstrated by confocal microscopy
using 100 mM galactose (Fig. 4d)
To further demonstrate the availability of
glycan ligands for galectin recognition and
immunoregulation, we next performed lectin-
histochemical analysis using biotinylated Gal-l and
Gal-3. Staining with biotinylated Gal-l revealed
the presence of Gal-l binding sites predominantly
on plasma cells, neutrophils and enterocytes (Fig.
5). Galectin-l binding strongly co-localized with
CD138 (Syndecan-l), a transmembrane heparan
sulfate proteoglycan highly expressed by plasma
cells. Importantly, Gal-l binding was inhibited by
addition of 100 mM lactose, clearly demonstrating
that this glycan-binding protein binds to plasma
cells in a saccharide-specific manner. Remarkably,
we found no significant differences in the extent of
Gal-l binding between gut samples of allergic and
non-allergic patients (Fig. 5). Of note, biotinylated
Gal-l was recognized by T cells in spleen biopsies
of control subjects (data not shown), yet it did
not bind to CD3+ T cells from intestinal biopsies,
suggesting that the presence of a2-6-linked sialic
acid on intraepithelial lymphocytes (Fig. 3 b, c)
might restrict Gal-l recognition of its specific glycan
ligands and limit its subsequent functional effects.
In contrast, biotinylated Gal-3 clearly bound
to macrophages, intraepithelial and lamina propria
T cells (Fig. 6). Also, the glycocalyx contained
glycosylated components capable of recognizing
Gal-3, as illustrated in Fig. 6a. Noteworthy, lectin-
histochemistry and confocal microscopic analyses
demonstrated substantially higher binding of Gal-3
to the surface of CD3+ intraepithelial T lymphocytes
in biopsies of allergic patients compared to non-
allergic subjects. Importantly, the total number of
IELs did not statistically differ between normal and
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allergic patients: 8.25 ± 0.78 and 8.37 ± 0.24 IELs
I villi (P= 0.9), respectively. However, the ratio of
Gal-S" IELs/total IELs per villi was 0.13 ± 0.05 for
normal subjects and 0.73 ± 0.14 for allergic patients,
clearly demonstrating that the transition from non-
allergic to allergic mucosal tissue results in selective
up-regulation of Gal-3-specific glycans on the
surface of IELs.
DISCUSSION
Research during the past decade has shed light on
the role of galectin-glycan interactions at different
stages of the inflammatory responses (5, 8, 13).
In addition, regulated expression of galectins, as
well as modulation of their specific ligands, is
a common feature of the transition from normal
to inflamed or neoplastic tissues (19-20). In this
study we characterized the pattern of Gal-l and
Gal-3 expression and their glycan-binding profiles
in mucosal duodenum of normal individuals and
allergic patients with a clinical outcome compatible
with hypersensitivity to cow milk proteins, in
an attempt to delineate the function of galectin-
glycan lattices within the intestinal inflammatory
microenvironment. Our results clearly demonstrate
that, in the absence of evident histopathologic
alterations, an early manifestation of cow milk
allergy is represented by an up-regulated expression
of Gal-3-binding sites on the surface ofIELs.
It still remains controversial whether the gut
mucosa is histologically altered as a result of
food allergy. Although no histological alteration
was found by Augustin and colleagues (21) in
CMSE patients, the authors observed a higher
density of TUNEU CD3+ IELs. This may reflect a
compensatory mechanism to eliminate IELs during
impaired immune responses to food allergens. In our
study we found no villous atrophy in the duodenum
of allergic patients. However, the presence of CD3+
IELs expressing the repertoire of glycans critical
for Gal-3 binding might contribute to alterations
of gut homeostasis and permeability. As Gal-3
has important pro-inflammatory properties (13), it
is possible that Gal-3-activated IELs might drive
inflammation and an uncontrolled response to food
antigens. Interestingly, in our study, samples of
allergic patients showed no considerable increase
in the number of CD3+ IELs, or in the frequency of
CD3+ cells infiltrating the lamina propria, although
most T cells were activated (CD3+CD45RO+ cells).
Kokkonen and colleagues (22) found similar results
in CMA patients with no villous atrophy or cell
infiltration. However, they found a higher density of
CD3+ y8+ IEL. Taken together, these results suggest
an increased number of IELs might be a marker of
young adult duodenum with CMSE.
Galectins and their specific glycan ligands are
abundant within the gastrointestinal tract (23-24).
Brinck and colleagues studied inflammation- and
neoplasia-associated alterations in human large
intestine and found critical differences in the lectin
binding profile following acute peritonitis and
tumorigenesis in the goblet cell population (24).
Previous studies reported that Gal-l and Gal-3
mRNA are weakly expressed in the lamina propria
ofthe small intestine (25). Conversely, we found that
epithelial cells and IELs were a major source ofGal-
1. This striking observation suggests that this lectin
might be involved in host-pathogen/commensal
interactions, in epithelial cell homeostasis, or in the
modulation of mucosal tolerance and inflammation.
This assumption is supported by the ability of
recombinant Gal-l to suppress inflammatory bowel
disease in mice (26). On the other hand, Gal-3,
which is mainly produced in the crypt, may also be
involved in epithelial cell proliferation or in immune
cell activation. Strikingly, we did not find differences
in Gal-lor Gal-3 expression between tissues from
non-allergic and allergic patients. As galectins are
regulated during pathological conditions (27-29),
further studies are warranted to analyze whether
galectin expression is modified in response to
allergic inflammation or following immunotherapy
in experimental models or clinical settings.
According to our results, Gal-l may not be
involved in lamina propria T cell (LPTC) homeostasis
although it clearly binds to peripheral T cells (6) or
to ThllTh17-skewed inflammatory mucosal T cells
(26). Thus, one might speculate that under steady-
state conditions or Th2-driven allergic responses,
mucosal T cells are decorated by u2-6-linked sialic
acid, thus restricting Gal-l binding and its subsequent
immunoregulatory effects (6). However, Gal-3 may
successfully regulate Th2-driven inflammation in the
mucosa during allergic inflammation, as has been
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previously demonstrated in mouse models (15-16).
Intriguingly, Gal-2, a proto-type galectin structurally
related to Gal-I, might playa compensatory role in
mucosal homeostasis as it is widely expressed within
the gastrointestinal tract (27).
Regarding the ligand selectivity of galectins,
it is apparent that neither Gal-l nor Gal-3 would
bind to glycans containing only one lactosamine
(Galpl,3(4)GlcNAc) with a2,6 sialyation on its
non-reducing terminal galactose residues, as the 6-
OH of the galactose residue is critical for galectin
binding. However, if a glycan contains more than
two lactosamine residues, one of which bearing a2,6
sialyation, a difference between Gal-l and Gal-3
glycan binding would then become evident. As Gal-
l preferentially recognizes peripheral (non-reducing
terminal) p-galactoside residues, the incorporation
of sialic acid in a2,6 linkage to the non-reducing
terminal galactoside may significantly reduce binding
of this lectin. In contrast, as Gal-3 binds to internal P-
galactoside residues, the impact ofsialyl modification
with a2,6 linkage is relatively lower than for Gal-L
As most glycans found on cell surface glycoproteins
contain more than two lactosamine residues, some of
which are not sialylated in a2,6, the overall affinity
of Gal-3 for a2,6 sialylated glycans looks higher than
Gal-l (9, 18).
In our study, SNA, which recognizes a2-6-linked
sialic acid, bound to membrane glycoproteins in
lamina propria macrophages, plasma cells and IELs at
the same extent in allergic and non-allergic patients.
This was confirmed by immunohistochemistry using
a specific anti-ST6Gall antibody supporting the fact
that Th2-polarized cells as well as other immune
cell types display abundant cell surface expression
of a2-6-linked sialic acid (5-6). On the other hand,
PNA, that specifically recognizes asialo-core-l-
O-glycans, labeled macrophages, epithelial cells
and mucin produced by goblet cells. In this regard,
PNA is a classical marker of immature thymocytes
and activated T cells (6), but can also recognize
macrophage glycoproteins (30). Of note, no PNA
binding to lamina propria T cells could be detected
in our study. Interestingly, we previously found that
human and mouse CD4+ T cells, polarized toward
Thl or Thl7 phenotypes, displayed abundant PNA-
reactive asialo-core-I-O-glycans. On the contrary,
Th2 cells showed limited PNA binding (6). In this
study, we found high PNA binding to intestinal
macrophages but not to T cells, an effect probably
associated with the high frequency of tolerogenic
and Th2-polarized cells in the mucosa of control
individuals or allergic patients.
The role of Gal-3 in allergic inflammation is still
controversial. Cortegano and colleagues showed an
anti-allergic effect by using recombinant Gal-3 to
suppress IL5 gene transcription in eosinophils and
allergen-specific T cell lines (16). On the contrary,
using Gal-3-deficient (LgalsY-) mice, Zuberi et
al. assigned a pro-inflammatory role for Gal-3 in a
mouse model of ovalbumin-induced asthma (15).
Interestingly, we found that IELs from allergic
patients differentially bind Gal-3, suggesting a
potential role of this glycan-binding protein in
modulating T cell homeostasis within the intestinal
mucosa in allergy. Further studies are necessary to
understand the effects of Gal-3 on IELs of CMSE
patients.
As previously mentioned, other groups have
reported that the density of IELs is often increased
in CMSE patients. A differential recognition of these
cells by Gal-3 in allergic patients may represent a
compensatory mechanism to restore tolerance and
homeostasis. Gal-3, although mostly described
as pro-inflammatory mediator, can also act as
an immunosuppressive agent by inducing T cell
apoptosis or negatively regulating T cell signaling
(5, 14). Hence, Gal-3 might exert a biphasic effect
acting as a pro-inflammatory molecule during
the first steps of allergic inflammation in early
childhood, while it might have a regulatory role in
limiting allergic processes in early adulthood. These
opposite functions might be exerted through the
recognition of differentially-glycosylated membrane
glycoproteins (14). Our findings suggest that the
transition from non-allergic to allergic inflammatory
intestinal microenvironment may result in selective
glycosylation changes mainly on the surface of
IELs.
In conclusion, our findings provide the first
evidence of a selective role of Gal-3 recognition
of IELs within the allergic inflammatory mucosa,
which may help to unveil the dominant mechanisms
underlying an impaired immune response to food
allergens. Future research is warranted to examine
the biological role of Gal-3-glycan lattices within
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the normal and inflamed mucosal tissue, and the
relevance of these multifunctional proteins in
positively or negatively regulating immunity and/or
tolerance within the intestinal microenvironment.
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